Skip to main content
. 2017 Mar 28;2017(3):CD011343. doi: 10.1002/14651858.CD011343.pub2

NCT02177136.

Trial name or title NCT02177136.
Methods Randomised, double‐blind, placebo‐controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions Obeticholic acid vs placebo.
Outcomes Adverse events.
Starting date December 2014.
Contact information kate.mckeown@interceptpharma.com
Notes